Literature DB >> 20979987

Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge.

Christine G Branger1, Wei Sun, Ascención Torres-Escobar, Robert Perry, Kenneth L Roland, Jacqueline Fetherston, Roy Curtiss.   

Abstract

We evaluated the ability of Yersinia pestis antigens HmuR, Psn and modified forms of LcrV delivered by live attenuated Salmonella strains to stimulate a protective immune response against subcutaneous or intranasal challenge with Y. pestis CO92. LcrV196 is a previously described truncated protein that includes aa 131-326 of LcrV and LcrV5214 has been modified to replace five key amino acids required for interaction with the TLR2 receptor. Psn is the outer membrane receptor for the siderophore, yersiniabactin, and the bacteriocin, pesticin. Mice immunized with Salmonella synthesizing Psn, LcrV196 or LcrV5214 developed serum IgG responses to the respective Yersinia antigen and were protected against pneumonic challenge with Y. pestis. Immunization with Salmonella synthesizing Psn or LcrV196 was sufficient to afford nearly full protection against bubonic challenge, while immunization with the strain synthesizing LcrV5214 was not protective. Immunization with Salmonella synthesizing HmuR, an outer membrane protein involved in heme acquisition in Y. pestis, was poorly immunogenic and did not elicit a protective response against either challenge route. These findings indicate that both Psn and LcrV196 delivered by Salmonella provide protection against both bubonic and pneumonic plague.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20979987      PMCID: PMC3014047          DOI: 10.1016/j.vaccine.2010.10.033

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  50 in total

Review 1.  Bacterial infectious disease control by vaccine development.

Authors:  Roy Curtiss
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

Review 2.  Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen).

Authors:  Robert R Brubaker
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

3.  Yersinia enterocolitica evasion of the host innate immune response by V antigen-induced IL-10 production of macrophages is abrogated in IL-10-deficient mice.

Authors:  Andreas Sing; Andreas Roggenkamp; Anna M Geiger; Jürgen Heesemann
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

4.  Identification and characterization of the hemophore-dependent heme acquisition system of Yersinia pestis.

Authors:  M S Rossi; J D Fetherston; S Létoffé; E Carniel; R D Perry; J M Ghigo
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

Review 5.  Vaccination against bubonic and pneumonic plague.

Authors:  R W Titball; E D Williamson
Journal:  Vaccine       Date:  2001-07-20       Impact factor: 3.641

6.  Genome sequence of Yersinia pestis, the causative agent of plague.

Authors:  J Parkhill; B W Wren; N R Thomson; R W Titball; M T Holden; M B Prentice; M Sebaihia; K D James; C Churcher; K L Mungall; S Baker; D Basham; S D Bentley; K Brooks; A M Cerdeño-Tárraga; T Chillingworth; A Cronin; R M Davies; P Davis; G Dougan; T Feltwell; N Hamlin; S Holroyd; K Jagels; A V Karlyshev; S Leather; S Moule; P C Oyston; M Quail; K Rutherford; M Simmonds; J Skelton; K Stevens; S Whitehead; B G Barrell
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

7.  Genetic organization of the yersiniabactin biosynthetic region and construction of avirulent mutants in Yersinia pestis.

Authors:  S W Bearden; J D Fetherston; R D Perry
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

8.  Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine.

Authors:  Ho Young Kang; Jay Srinivasan; Roy Curtiss
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

9.  Live recombinant Salmonella Typhi vaccines constructed to investigate the role of rpoS in eliciting immunity to a heterologous antigen.

Authors:  Huoying Shi; Javier Santander; Karen E Brenneman; Soo-Young Wanda; Shifeng Wang; Patti Senechal; Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  PLoS One       Date:  2010-06-18       Impact factor: 3.240

10.  Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression.

Authors:  Andreas Sing; Dagmar Rost; Natalia Tvardovskaia; Andreas Roggenkamp; Agnès Wiedemann; Carsten J Kirschning; Martin Aepfelbacher; Jürgen Heesemann
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

View more
  17 in total

Review 1.  Developing live vaccines against plague.

Authors:  Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  J Infect Dev Ctries       Date:  2011-09-14       Impact factor: 0.968

2.  Oral administration of a recombinant attenuated Yersinia pseudotuberculosis strain elicits protective immunity against plague.

Authors:  Wei Sun; Shilpa Sanapala; Hannah Rahav; Roy Curtiss
Journal:  Vaccine       Date:  2015-10-26       Impact factor: 3.641

3.  Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.

Authors:  Paul M Arnaboldi; Mariya Sambir; Christina D'Arco; Lauren A Peters; Jos F M L Seegers; Lloyd Mayer; Alison A McCormick; Raymond J Dattwyler
Journal:  Vaccine       Date:  2016-10-13       Impact factor: 3.641

4.  Blocking yersiniabactin import attenuates extraintestinal pathogenic Escherichia coli in cystitis and pyelonephritis and represents a novel target to prevent urinary tract infection.

Authors:  Ariel R Brumbaugh; Sara N Smith; Sargurunathan Subashchandrabose; Stephanie D Himpsl; Tracy H Hazen; David A Rasko; Harry L T Mobley
Journal:  Infect Immun       Date:  2015-01-26       Impact factor: 3.441

5.  LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.

Authors:  Wei Sun; Shilpa Sanapala; Jeremy C Henderson; Shandiin Sam; Joseph Olinzock; M Stephen Trent; Roy Curtiss
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

6.  Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.

Authors:  Tatiana E Erova; Jason A Rosenzweig; Jian Sha; Giovanni Suarez; Johanna C Sierra; Michelle L Kirtley; Christina J van Lier; Maxim V Telepnev; Vladimir L Motin; Ashok K Chopra
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

7.  Yersinia pseudotuberculosis Prevalence and Diversity in Wild Boars in Northeast Germany.

Authors:  Marie Reinhardt; Jens Andre Hammerl; Katharina Kunz; Andrea Barac; Karsten Nöckler; Stefan Hertwig
Journal:  Appl Environ Microbiol       Date:  2018-08-31       Impact factor: 4.792

8.  Amino acid substitutions in LcrV at putative sites of interaction with Toll-like receptor 2 do not affect the virulence of Yersinia pestis.

Authors:  Wei Sun; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-07-24       Impact factor: 3.738

9.  Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague.

Authors:  Shilpa Sanapala; Hannah Rahav; Hetal Patel; Wei Sun; Roy Curtiss
Journal:  Vaccine       Date:  2016-04-06       Impact factor: 3.641

10.  Evaluation of YadC protein delivered by live attenuated Salmonella as a vaccine against plague.

Authors:  Wei Sun; Joseph Olinzock; Shifeng Wang; Shilpa Sanapala; Roy Curtiss
Journal:  Pathog Dis       Date:  2013-09-10       Impact factor: 3.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.